Newborn Screening Market Size, Share, Growth Factors, Analysis and Forecast 2026-2034

According to IMARC Group, the global newborn screening market size reached USD 1,153.1 Million in 2025 and is projected to reach USD 1,877.2 Million by 2034, expanding at a CAGR of 5.60% during 2026–2034. This steady newborn screening market growth reflects rising awareness of early disease detection, continuous improvements in diagnostic technology, and favorable government initiatives mandating comprehensive screening panels across the globe.

Newborn Screening Industry Overview

Newborn screening is a public health program designed to identify specific genetic, metabolic, hormonal, or functional conditions in newborns shortly after birth. It involves a series of tests performed within the first few days of life to detect potentially serious disorders that may not be immediately apparent but could lead to severe health complications, developmental delays, or death if left untreated.

Newborn screening programs are deployed across a broad continuum of use cases:

• Metabolic disorder screening: Detection of inborn errors of metabolism such as phenylketonuria (PKU) and other conditions identifiable through dried blood spot analysis
• Endocrine and genetic disorder screening: Congenital hypothyroidism, congenital adrenal hyperplasia, and inherited genetic conditions
• Cardiac screening: Critical congenital heart disease (CCHD) detection through pulse oximetry
• Hearing screening: Early identification of congenital hearing loss to support timely intervention
• Hemoglobinopathy and infectious condition screening: Enzyme-based and DNA assay testing for a widening panel of inherited and acquired disorders

Global Newborn Screening Market Size & Key Statistics

Below are the key newborn screening market statistics drawn from IMARC Group's comprehensive market analysis:

Request for a Sample Report for Detailed Newborn Screening Market Share Evaluation: https://www.imarcgroup.com/newborn-screening-market/requestsample

Key Market Drivers & Newborn Screening Market Trends in 2026

Several powerful forces are shaping Newborn Screening Market Trends and fuelling sustained growth expectations across global public health and diagnostics markets:

1. Increasing Awareness About Early Disease Detection

The growing awareness among parents toward the critical importance of early disease detection — enhancing treatment outcomes, improving quality of life for the child, and enabling timely intervention — represents one of the primary drivers bolstering the market. The rising occurrence of congenital diseases is also acting as a significant growth-inducing factor; reports indicate that about two to three children out of every 1,000 in the United States have cerebral palsy.

2. Favorable Government Initiatives

The launch of policies by regulatory authorities that often cover a comprehensive panel of disorders and ensure potential health issues are addressed efficiently is bolstering the global market. For example, in June 2022, government bodies in Manitoba, Canada, announced the expansion of their newborn screening program to extend screening for spinal muscular atrophy, among other diseases. Various government authorities have also made newborn screening compulsory before hospital discharge, positively impacting overall Newborn Screening Market Growth.

3. Improvements in Medical Technology

Key players are advancing their medical technologies to improve newborn screening methods, acting as another significant growth-inducing factor. In June 2021, the Texas Department of State Health Services introduced newborn screening for Spinal Muscular Atrophy (SMA). In 2022, Trivitron Healthcare developed a Centre of Excellence with state-of-the-art R&D and manufacturing facilities at the AMTZ Campus in India for genomics, newborn screening, metabolomics, and molecular diagnostics. In January 2023, Masimo announced the launch of a new state-of-the-art baby monitoring system allowing caretakers to monitor infant data in real time.

4. Expansion of Tandem Mass Spectrometry and Enzyme-Linked Immunoassay Testing

Extensions in the field of tandem mass spectrometry and enzyme-linked immunoassays have increased the sensitivity and specificity required by screening tests, improving overall adoption. Tandem mass spectrometry alone accounts for around 23.8% of the Newborn Screening Market Share in 2025, reflecting its central role in identifying metabolic disorders with improved accuracy and speed.

5. Rising Incidence of Congenital and Inherited Metabolic Disorders

The rising incidence of congenital anomalies and inherited metabolic disorders makes early diagnosis highly imperative, placing newborn screening systems as a top priority in public health policy across both developed and emerging economies.

6. Development of Non-Invasive and Point-of-Care Screening Techniques

The development of non-invasive screening techniques, such as dried blood spot collection and pulse oximetry, offers safer and more efficient testing options. Dry blood spot testing alone commands roughly 46.5% of Newborn Screening Market Share by test type in 2025, owing to its ease of transportation, convenience of sample collection, and ability to simultaneously screen for multiple conditions.

Key Market Segmentation

By Product

Instruments — Largest Segment: Instruments held around 77.6% of the market in 2025. They play a crucial role in the screening process for sample collection, analysis, and result interpretation, comprising technologies such as DNA analyzers, automated screening platforms, and mass spectrometry systems. Rising investments by key healthcare companies in diagnostics requiring instrumentation, such as GC Labs' March 2023 launch of a new Inborn Errors of Metabolism (IEM) test, continue to bolster this segment.

Reagents: Reagents support the recurring, consumable-driven side of the market, supplying the calibrators, kits, and assay components required for each screening test performed.

By Technology

Tandem Mass Spectrometry — Largest Segment: Tandem mass spectrometry leads the technology segment with around 23.8% of Newborn Screening Market Share in 2025. It is an analytical technique used to identify multiple metabolic disorders with improved accuracy and speed, and continues to benefit from technological advancement, such as Waters Corporation's April 2023 launch of the Xevo TQ Absolute IVD Mass Spectrometer for clinical applications.

Other technologies covered include Pulse Oximetry, Enzyme Based Assay, DNA Assay, Electrophoresis, and Others.

By Test Type

Dry Blood Spot Test — Largest Segment: Dry blood spot testing leads with around 46.5% of market share in 2025. This non-invasive technique involves collecting a small blood sample from a newborn's heel onto filter paper, which is then analyzed for markers associated with multiple disorders — offering ease of transportation, convenient sample collection, and the ability to screen for several conditions simultaneously.

Additional test types covered include Critical Congenital Heart Disease (CCHD) screening and Hearing Screen.

Regional Newborn Screening Market Analysis

North America leads the global Newborn Screening Market Share, underpinned by comprehensive state-level screening mandates in the United States, broad insurance coverage, and continued adoption of tandem mass spectrometry and next-generation sequencing across core public health laboratories. Within the region, the United States alone accounts for 86.80% of North American market value.

Asia Pacific represents a fast-expanding regional market, driven by the establishment and expansion of nationwide screening programs, growing urban healthcare infrastructure, and rising incidence of genetic disorders across China, India, Japan, and other economies in the region.

Connect for Detailed Newborn Screening Market Share Segmentation Analysis — Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=4068&flag=C

Leading Players in the Global Newborn Screening Industry

The global newborn screening market features a mix of diversified diagnostics multinationals and specialized screening technology providers. Key companies covered in the IMARC Group report include:

Latest Newborn Screening Market Industry Developments

March 2024 — Niloufer Hospital, Hyderabad

A newborn screening program aimed at identifying rare and severe genetic conditions in infants was launched at the state-operated Niloufer Hospital in Hyderabad. The screening was implemented to detect conditions such as congenital hypothyroidism, congenital adrenal hyperplasia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, galactosemia, and biotinidase deficiency.

March 2024 — World Health Organization

The WHO launched implementation guidance in the South-East Asia Region for universal screening of newborns for hearing impairment, eye abnormalities, and neonatal jaundice, aimed at mitigating disability risk through early detection and appropriate management.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104